Eisai

A→Z catalog of Eisai

A

• Acalabrutinib (Calquence, co-commercial with AZ in Japan) — Acalabrutinib — CLL, SLL, MCL — 100 mg BID.

• Aricept — Donepezil hydrochloride — Alzheimer’s disease, dementia with Lewy bodies — 5–10 mg QD (max 23 mg ER).

• Adcetris (with Takeda in Japan) — Brentuximab vedotin — Hodgkin lymphoma, ALCL — IV infusion q3w.

• Amanon (Japan generics line) — Amantadine — Parkinson’s disease, influenza.

• Antirust (regional) — Famotidine combos.

B

• Belviq (withdrawn US, still Eisai-developed) — Lorcaserin — Obesity — 10 mg BID.

• Blenrep (regional co-market) — Belantamab mafodotin.

• Binimetinib (via alliance, Japan rights) — Melanoma, NSCLC (combo).

C

• Carboplatin Eisai — Carboplatin — Oncology — AUC dosing.

• Cisplatin Eisai — Cisplatin — Solid tumors — 50–100 mg/m² IV.

• Chocola BB series (Japan OTC) — Vitamin B complex supplements for fatigue, skin health.

• Chocola BB Plus / BB Pure / BB Royal T — OTC line.

• Chocola Collagen Beauty — OTC nutraceutical.

D

• Dayvigo — Lemborexant — Insomnia — 5–10 mg HS.

• Decadron Eisai (Japan co-supply) — Dexamethasone.

• Dostarlimab (co-commercial in Japan, alliance with GSK) — dMMR cancers.

E

• Eribulin (Halaven) — Eribulin mesylate — Metastatic breast cancer, liposarcoma — 1.4 mg/m² IV Days 1 & 8 q21d.

• Epoetin Alfa Biosimilar (Japan, Epoetin kenketsu) — Anemia.

• Econazole creams (Japan generics line).

F

• Fycompa — Perampanel — Focal/generalized seizures in epilepsy — Start 2 mg HS → titrate to 8–12 mg HS.

• Fosdenopterin (Nulibry Japan alliance).

• Famotidine Eisai generics — GERD, ulcers — 20 mg BID.

G

• Gliadel Wafer — Carmustine biodegradable implant — Malignant glioma (HGG, GBM) — Wafer implantation during surgery.

• Gasmotin — Mosapride citrate — Functional dyspepsia, GERD — 5 mg TID.

• Gardasil (Japan co-market with MSD) — HPV vaccine.

H

• Halaven — see E.

• Humira co-promotion Japan (with AbbVie).

• Helican (regional generics) — Helicobacter pylori eradication kit.

I

• Ismo — Isosorbide mononitrate/dinitrate — Angina prophylaxis — 20–40 mg BID (isosorbide mononitrate).

• Imfinzi co-promote in Japan (with AZ).

• Idursulfase beta (Hunterase, Japan) — Idursulfase beta — Hunter syndrome (MPS II).

J

• Juvela (OTC Japan) — Vitamin E supplement.

K

• Kinpeygo (filgotinib, co-market in Japan).

• Kinedak — Epalrestat — Diabetic neuropathy — 50 mg TID.

• Kyprolis (Amgen, co-market Japan) — Carfilzomib.

L

• Lenvima — Lenvatinib mesylate — HCC, thyroid, endometrial, RCC — 8–24 mg QD depending on weight/indication.

• Leqembi (Leqembi/Leqembi) — Lecanemab (with Biogen) — Alzheimer’s disease — 10 mg/kg IV q2w (maintenance).

• Lusedra (discontinued US, Japan use) — Fospropofol — Sedation.

• Loxonin co-supply (Japan generics) — Loxoprofen.

M

• Methycobal — Mecobalamin (Vitamin B12) — Peripheral neuropathy — 500–1500 mcg/day PO or injection.

• Mircera (co-promote Japan with Roche) — Methoxy-PEG epoetin beta.

• Mekinist (Japan co-market with Novartis) — Trametinib.

N

• Nexium co-promotion in Japan (with AZ).

• Nexipod injection devices (biosimilars Japan).

• Nexipla generics.

• Nivolumab (Opdivo, co-commercial BMS in Japan).

• Nexipod (subcutaneous injection system, Japan).

O

• OncoTICE (co-market Japan) — BCG intravesical — Bladder cancer.

• Orpathys co-promote Japan (savolitinib).

• Ongentys distribution Japan (opicapone).

• Onglyza Japan co-market.

P

• Pariet / AcipHex — Rabeprazole sodium — GERD, peptic ulcers — 10–20 mg QD.

• Perampanel (Fycompa) — see F.

• Prialt distribution (ziconotide, Japan EU).

Q

• Quetapin generics (Japan) — Quetiapine fumarate.

R

• RevMate — Risk management program for thalidomide analogues in Japan.

• RevMate Thalidomide (Japan).

• RevMate Lenalidomide (Japan).

• Rabeprazole — see P.

S

• Selbex — Teprenone — Gastritis — 50 mg TID.

• Somatuline Japan alliance.

• Suplatast Tosilate (IPD) — Allergic disorders — 100 mg BID.

• Sandoz co-branded generics Japan (Eisai generics).

T

• Treakisym (Japan) — Bendamustine — Hematological malignancies.

• Trobalt (retigabine; legacy EU use) — Epilepsy — 600–1200 mg/day.

• Thalidomide (RevMate Japan) — Multiple myeloma, ENL — 100–200 mg daily.

U

• Urorec co-promote Japan (silodosin) — BPH — 8 mg daily.

• Uloric distribution Japan (febuxostat).

V

• Vizimpro Japan distribution (dacomitinib).

• Vandetanib (Japan distribution).

• Vaccines (Eisai Japan co-markets influenza, HPV, pneumococcal with partners).

W

• Wellion nutritional lines Japan (OTC).

X

• Xospata co-distribution Japan (gilteritinib).

• Xtandi co-commercialization Japan (enzalutamide).

Y

• Yondelis Japan (trabectedin, with Janssen/Takeda).

Z

• Zebinix distribution Japan (eslicarbazepine).

• Zonisamide Eisai — Zonisamide — Epilepsy, Parkinson’s — 100–400 mg/day.

• Zymeta generics — Zoledronic acid.

•